What is B. Riley’s Forecast for CGTX FY2026 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – B. Riley issued their FY2026 earnings estimates for Cognition Therapeutics in a report issued on Thursday, February 6th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.71) per share for the year. B. Riley currently has a “Buy” rating and a $1.50 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. B. Riley also issued estimates for Cognition Therapeutics’ FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.54) EPS.

A number of other research analysts have also issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $11.00 target price on shares of Cognition Therapeutics in a report on Thursday, December 19th. HC Wainwright lifted their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $8.30.

Cognition Therapeutics Stock Down 1.9 %

Shares of CGTX opened at $0.64 on Friday. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95. The firm’s 50 day moving average price is $0.64 and its 200 day moving average price is $0.64.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Cognition Therapeutics in the 4th quarter valued at $26,000. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $27,000. Finally, Sigma Planning Corp boosted its stake in shares of Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.